GO:0047057 vitamin-K-epoxide reductase (warfarin-sensitive) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047057 describes the warfarin-sensitive vitamin K epoxide reductase activity that reduces vitamin K 2,3-epoxide back to the reduced hydroquinone form, a reaction essential for recycling vitamin K in the endoplasmic reticulum membrane.
• The catalytic reaction converts phylloquinol and a protein disulfide into phylloquinone and a protein with reduced L-cysteine residues, coupling vitamin K oxidation to protein thiol formation.
• The enzyme complex is assembled in the endoplasmic reticulum membrane and includes VKORC1 and associated redox proteins such as protein disulfide isomerase.
• Warfarin and other 4-hydroxycoumarin anticoagulants inhibit this activity stereoselectively, forming the pharmacological basis of vitamin K antagonist therapy.
• VKORC1L1, a paralog of VKORC1, regulates vitamin K metabolism and is critical for p53-mediated tumor suppression, linking this activity to cancer biology.
• Vitamin K epoxide reductase activity also modulates androgen receptor activity, suggesting broader roles in nuclear receptor signaling beyond coagulation.
Description
Vitamin-K-epoxide reductase (warfarin-sensitive) activity, encoded by GO:0047057, is a molecular function that catalyzes the reduction of vitamin K 2,3-epoxide to the reduced hydroquinone form, using a protein disulfide as an electron acceptor. This activity is a central component of the vitamin K cycle, a metabolic pathway that regenerates reduced vitamin K for gamma-glutamyl carboxylation of vitamin K-dependent proteins involved in blood coagulation and bone metabolism. The warfarin-sensitive nature of this activity has made it a long-standing target for anticoagulant therapy, and its stereoselective inhibition by 4-hydroxycoumarin derivatives has been extensively characterized. Researchers study GO:0047057 to understand the molecular basis of vitamin K homeostasis, the pharmacology of anticoagulants, and the emerging roles of vitamin K metabolism in cancer and other diseases. The enzyme complex is embedded in the endoplasmic reticulum membrane and requires redox partners such as protein disulfide isomerase for optimal activity. Recent work has shown that overexpression of protein disulfide isomerase enhances vitamin K epoxide reductase activity, highlighting the importance of the redox environment in regulating this function. Additionally, the human vitamin K epoxide reductase has been identified as a target of its redox protein, providing mechanistic insights into the electron transfer chain. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0047057, its genes, mechanisms, and experimental approaches.
vitamin-K-epoxide reductase (warfarin-sensitive) activity At A Glance
| GO ID | GO:0047057 |
|---|---|
| GO term | vitamin-K-epoxide reductase (warfarin-sensitive) activity |
| Ontology | molecular_function |
| Synonym | phylloquinone epoxide reductase activity; vitamin K1 epoxide reductase activity |
| Definition | Catalysis of the reaction: phylloquinol + a protein with a disulfide bond = phylloquinone + a protein with reduced L-cysteine residues. |
| Major function | Reduction of vitamin K 2,3-epoxide to phylloquinol, coupled to protein disulfide reduction, in the vitamin K cycle. |
| Warfarin sensitivity | Inhibited by warfarin and other 4-hydroxycoumarin anticoagulants. |
| Cellular location | Endoplasmic reticulum membrane. |
| Key enzyme | VKORC1 (vitamin K epoxide reductase complex subunit 1). |
What Is GO:0047057?
GO:0047057 is defined as the catalysis of the reaction: phylloquinol + a protein with a disulfide bond = phylloquinone + a protein with reduced L-cysteine residues. In other words, this activity reduces vitamin K 2,3-epoxide (phylloquinone epoxide) to its hydroquinone form (phylloquinol) while simultaneously reducing a protein disulfide bond to free thiols. The reaction is warfarin-sensitive, meaning it is inhibited by warfarin and related 4-hydroxycoumarin anticoagulants. Synonyms include phylloquinone epoxide reductase activity and vitamin K1 epoxide reductase activity. This molecular function is a key step in the vitamin K cycle, which maintains reduced vitamin K pools for post-translational gamma-carboxylation of glutamate residues in vitamin K-dependent proteins.
Why Is vitamin-K-epoxide reductase (warfarin-sensitive) activity Important in Cell Biology?
GO:0047057 is essential for the vitamin K cycle, which supplies reduced vitamin K for gamma-carboxylation of coagulation factors II, VII, IX, and X, as well as proteins involved in bone and vascular health. The warfarin-sensitive nature of this activity makes it the pharmacological target of one of the most widely prescribed anticoagulants, and interindividual variability in VKORC1 affects warfarin dose requirements. Beyond coagulation, vitamin K epoxide reductase activity has been implicated in cancer biology through VKORC1L1-mediated regulation of p53 tumor suppression and in androgen receptor signaling. Understanding this activity at molecular and structural levels is therefore critical for drug development, personalized medicine, and fundamental cell biology.
• Central to the vitamin K cycle, maintaining reduced vitamin K for gamma-carboxylation of clotting factors.
• Pharmacological target of warfarin and other 4-hydroxycoumarin anticoagulants.
• Stereoselective inhibition by warfarin underlies clinical anticoagulant efficacy and dosing variability.
• VKORC1L1, a paralog, regulates p53-mediated tumor suppression via vitamin K metabolism.
• Modulates androgen receptor activity, linking vitamin K metabolism to nuclear receptor signaling.
• Protein disulfide isomerase enhances VKOR activity, revealing redox regulation of the enzyme.
• Enzyme complex assembly in the endoplasmic reticulum membrane is required for activity.
• Human VKOR is a target of its redox protein, providing a model for electron transfer.
• Vitamin K epoxide reductase is present in photosynthetic organisms, suggesting evolutionary conservation.
• Dysregulation of vitamin K metabolism may contribute to cancer and other diseases.
Molecular Mechanism of vitamin-K-epoxide reductase (warfarin-sensitive) activity
Substrate binding and catalytic reaction
In simple terms: The enzyme grabs vitamin K epoxide and a protein with a disulfide bond, then converts them into vitamin K hydroquinone and a protein with free thiols.
The catalytic mechanism of GO:0047057 involves the reduction of phylloquinone epoxide to phylloquinol, coupled with the reduction of a protein disulfide bond to two cysteine thiols. The reaction is stereoselective, and the enzyme complex assembles in the endoplasmic reticulum membrane to facilitate electron transfer. The warfarin-sensitive step is the reduction of vitamin K 2,3-epoxide, which is inhibited by 4-hydroxycoumarin anticoagulants.
Role of protein disulfide isomerase and redox partners
In simple terms: Other proteins help the enzyme by providing or recycling the disulfide bonds needed for the reaction.
Protein disulfide isomerase (PDI) enhances vitamin K epoxide reductase activity, likely by maintaining the redox state of the enzyme or providing disulfide substrates. The human vitamin K epoxide reductase has been shown to be a target of its redox protein, suggesting a direct electron transfer pathway. Overexpression of PDI increases VKOR activity, indicating that the redox environment is a key regulator.
Warfarin sensitivity and inhibition
In simple terms: Warfarin blocks this enzyme by mimicking vitamin K, which is why it works as a blood thinner.
Warfarin and other 4-hydroxycoumarin anticoagulants inhibit GO:0047057 by competing with vitamin K epoxide, and the inhibition is stereoselective. The warfarin-sensitive nature of the enzyme complex is a defining feature of this activity, as demonstrated by assembly studies in the endoplasmic reticulum membrane. This inhibition reduces the regeneration of reduced vitamin K, leading to decreased gamma-carboxylation of clotting factors.
Assembly of the enzyme complex in the endoplasmic reticulum
In simple terms: The enzyme is built into the membrane of the endoplasmic reticulum, where it can access vitamin K and redox partners.
The warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex assembles in the endoplasmic reticulum membrane, requiring specific membrane components for activity. The complex includes VKORC1 and associated proteins that facilitate electron transfer. This membrane localization is essential for the enzyme to interact with its lipid-soluble substrate, vitamin K epoxide.
Vitamin K cycle and physiological significance
In simple terms: This enzyme is part of a cycle that recycles vitamin K so the body can keep making clotting factors.
GO:0047057 is a critical step in the vitamin K cycle, which regenerates reduced vitamin K for gamma-glutamyl carboxylation of vitamin K-dependent proteins. The cycle involves oxidation of vitamin K hydroquinone to epoxide and its subsequent reduction by VKOR. Disruption of this cycle by warfarin or genetic variants leads to impaired clotting and other physiological consequences.
Evolutionary and comparative aspects
In simple terms: Similar enzymes are found in plants and other organisms, showing this activity is ancient.
Vitamin K epoxide reductase activity has been identified in photosynthetic organisms, indicating evolutionary conservation of vitamin K metabolism. This suggests that the basic mechanism of GO:0047057 predates the divergence of plants and animals. Comparative studies may reveal conserved structural features and catalytic residues.
Key Genes Involved in GO:0047057 vitamin-K-epoxide reductase (warfarin-sensitive) activity
The following genes and proteins are directly implicated in vitamin-K-epoxide reductase (warfarin-sensitive) activity, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VKORC1 | Catalytic subunit of the vitamin K epoxide reductase complex; primary target of warfarin | Determines warfarin sensitivity and vitamin K cycle efficiency |
| VKORC1L1 | Paralog of VKORC1; regulates vitamin K metabolism and p53-mediated tumor suppression | Links vitamin K metabolism to cancer |
| PDI | Protein disulfide isomerase; enhances VKOR activity and provides redox support | Modulates enzyme activity via redox regulation |
| AR | Androgen receptor; activity regulated by vitamin K epoxide reductase | Connects vitamin K metabolism to nuclear receptor signaling |
| p53 | Tumor suppressor; regulated by VKORC1L1-mediated vitamin K metabolism | Implicates vitamin K cycle in tumor suppression |
| GGCX | Gamma-glutamyl carboxylase; uses reduced vitamin K produced by VKOR | Downstream effector of the vitamin K cycle |
| F2 | Prothrombin; vitamin K-dependent clotting factor | Clinical readout of VKOR activity |
| F7 | Factor VII; vitamin K-dependent clotting factor | Clinical readout of VKOR activity |
| F9 | Factor IX; vitamin K-dependent clotting factor | Clinical readout of VKOR activity |
| F10 | Factor X; vitamin K-dependent clotting factor | Clinical readout of VKOR activity |
| PROC | Protein C; vitamin K-dependent anticoagulant | Affected by warfarin therapy |
| PROS1 | Protein S; vitamin K-dependent anticoagulant | Affected by warfarin therapy |
| BGLAP | Osteocalcin; vitamin K-dependent bone protein | Links vitamin K cycle to bone health |
| MGP | Matrix Gla protein; vitamin K-dependent vascular protein | Links vitamin K cycle to vascular calcification |
| GAS6 | Growth arrest-specific 6; vitamin K-dependent protein | Potential role in cell survival |
| CYP2C9 | Cytochrome P450; metabolizes warfarin | Influences warfarin dose response |
| VKORC1 promoter | Regulatory region; affects VKORC1 expression | Pharmacogenomic marker for warfarin dosing |
How Is vitamin-K-epoxide reductase (warfarin-sensitive) activity Regulated?
The activity of vitamin-K-epoxide reductase (warfarin-sensitive) is regulated at multiple levels. Protein disulfide isomerase enhances VKOR activity, indicating redox-dependent regulation. The human VKOR is a target of its redox protein, suggesting feedback or electron transfer control. Warfarin and other 4-hydroxycoumarin anticoagulants inhibit the enzyme stereoselectively, providing pharmacological regulation. Additionally, VKORC1L1 is regulated by p53, linking vitamin K metabolism to tumor suppressor pathways. The assembly of the enzyme complex in the endoplasmic reticulum membrane is also a regulatory step.
vitamin-K-epoxide reductase (warfarin-sensitive) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VKORC1 | Warfarin sensitivity, coagulation disorders | Knock-in mouse models with human VKORC1 variants; hepatocyte cell lines |
| VKORC1L1 | Cancer, p53-mediated tumor suppression | VKORC1L1 knockout cancer cell lines; xenograft models |
| AR | Prostate cancer, androgen signaling | AR-positive prostate cancer cells with VKOR modulation |
| PDI | Redox regulation, thrombosis | PDI overexpression or knockout in endothelial cells |
| GGCX | Vitamin K-dependent bleeding disorders | GGCX knockout cell models; coagulation factor assays |
Warfarin sensitivity and coagulation disorders
Genetic variants in VKORC1 affect warfarin dose requirements and the risk of bleeding or thrombosis. The warfarin-sensitive activity of GO:0047057 is the pharmacological target of coumarin anticoagulants, and interindividual variability in this activity underlies differences in drug response. Deficiencies in vitamin K-dependent clotting factors due to impaired VKOR activity can lead to bleeding disorders.
Cancer and tumor suppression
VKORC1L1, a paralog of VKORC1, regulates vitamin K metabolism and is critical for p53-mediated tumor suppression. Loss of VKORC1L1 impairs p53 function and promotes tumorigenesis in certain contexts. This links GO:0047057-related activity to cancer biology and suggests that vitamin K metabolism may be a therapeutic target.
Androgen receptor signaling and prostate cancer
Vitamin K epoxide reductase regulates androgen receptor activity, indicating a role in hormone-dependent cancers such as prostate cancer. Modulation of VKOR activity may affect androgen receptor transcriptional output and cell proliferation. This provides a rationale for investigating vitamin K metabolism in endocrine-related malignancies.
Vitamin K deficiency and bone/vascular health
Impaired vitamin K cycle activity can lead to insufficient gamma-carboxylation of bone and vascular proteins, contributing to osteoporosis and vascular calcification. Vitamin K-dependent proteins such as osteocalcin and matrix Gla protein require reduced vitamin K generated by VKOR. Thus, GO:0047057 dysfunction may have implications beyond coagulation.
From vitamin-K-epoxide reductase (warfarin-sensitive) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does VKORC1 loss abolish vitamin K epoxide reductase activity? | VKORC1 knockout cell lines (e.g., HEK293, HepG2) |
| How do warfarin-resistance mutations affect enzyme function? | Point-mutation knock-in of VKORC1 variants in cell lines |
| Can tagged VKORC1 be used to study complex assembly? | Knock-in of epitope-tagged VKORC1 in endoplasmic reticulum membranes |
| Does VKORC1L1 overexpression affect p53 target genes? | VKORC1L1 overexpression in cancer cell lines |
| Does PDI modulate VKOR activity? | PDI overexpression or knockdown in VKOR-expressing cells |
| How does VKOR activity affect androgen receptor signaling? | AR-positive cells with VKORC1 knockout or overexpression |
How to Study the vitamin-K-epoxide reductase (warfarin-sensitive) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HPLC/LC-MS enzyme assay | Conversion of vitamin K epoxide to phylloquinol | Measuring VKOR activity in membrane fractions |
| Co-immunoprecipitation | Protein-protein interactions in the VKOR complex | Studying assembly with PDI and other partners |
| RNA-seq | Transcriptional changes upon VKOR modulation | Identifying p53 or AR target genes |
| Proteomics | Gamma-carboxylation status of vitamin K-dependent proteins | Assessing downstream effects of VKOR activity |
| Redox proteomics | Disulfide bond formation and reduction | Identifying redox targets of VKOR |
| CRISPR knockout screening | Genes required for VKOR activity or warfarin sensitivity | Functional genomics of vitamin K metabolism |
| Reporter assays | Androgen receptor transcriptional activity | Linking VKOR to AR signaling |
| Blue native PAGE | Intact membrane protein complexes | Analyzing VKOR complex assembly |
Enzymatic activity assays
Vitamin K epoxide reductase activity can be measured using membrane fractions from cells or tissues by monitoring the conversion of vitamin K 2,3-epoxide to phylloquinol, often with HPLC or LC-MS detection. Warfarin sensitivity is assessed by adding warfarin to the assay and measuring inhibition. These assays are foundational for studying GO:0047057.
Protein interaction and complex assembly studies
Co-immunoprecipitation and blue native PAGE can be used to study the assembly of the VKOR complex in the endoplasmic reticulum membrane. Tagged VKORC1 knock-in models facilitate purification and interaction studies. Redox protein partners such as PDI can be identified by crosslinking or proximity labeling.
Gene expression and transcriptomics
RNA-seq can quantify expression of VKORC1, VKORC1L1, and vitamin K-dependent genes under different conditions. Knockout or overexpression models followed by RNA-seq reveal downstream transcriptional changes, such as p53 target genes. This approach helps link GO:0047057 to cellular pathways.
Proteomics and post-translational modification analysis
Mass spectrometry-based proteomics can assess gamma-carboxylation status of vitamin K-dependent proteins as a readout of VKOR activity. Redox proteomics can identify protein disulfide targets of VKOR. These methods provide systems-level insights into the vitamin K cycle.
How CRISPR Can Be Used to Study GO:0047057 vitamin-K-epoxide reductase (warfarin-sensitive) activity
Knockout
CRISPR knockout of VKORC1 or VKORC1L1 can abolish vitamin K epoxide reductase activity, providing a clean background to study GO:0047057. Knockout cell lines are useful for measuring warfarin sensitivity and downstream effects on gamma-carboxylation. These models can also reveal compensatory mechanisms by other reductases.
Point Mutation
Point mutations in VKORC1 that confer warfarin resistance can be introduced using CRISPR base editing or homology-directed repair. Such models help dissect the stereoselective inhibition by 4-hydroxycoumarins. They also inform pharmacogenomic studies of warfarin dosing.
Knock-in
Knock-in of epitope-tagged VKORC1 allows for affinity purification and localization studies in the endoplasmic reticulum. Knock-in of human VKORC1 variants into mouse models can mimic human warfarin sensitivity. These models are valuable for studying complex assembly and function in vivo.
Overexpression
Overexpression of VKORC1 or VKORC1L1 can enhance vitamin K epoxide reductase activity and modulate downstream pathways such as p53 tumor suppression. Overexpression of PDI alongside VKOR can further boost activity, highlighting redox regulation. These models are useful for gain-of-function studies and drug screening.
How EDITGENE Supports vitamin-K-epoxide reductase (warfarin-sensitive) activity Research
Researchers studying vitamin-K-epoxide reductase (warfarin-sensitive) activity-related genes often need to determine whether a candidate gene is causally involved in vitamin K metabolism, coagulation, or cancer. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for vitamin-K-epoxide reductase (warfarin-sensitive) activity research.
Frequently Asked Questions About vitamin-K-epoxide reductase (warfarin-sensitive) activity
What is vitamin-K-epoxide reductase (warfarin-sensitive) activity?
It is a molecular function (GO:0047057) that catalyzes the reduction of vitamin K 2,3-epoxide to phylloquinol, coupled to protein disulfide reduction, and is inhibited by warfarin.
What genes are involved in vitamin-K-epoxide reductase (warfarin-sensitive) activity?
Key genes include VKORC1, VKORC1L1, PDI, and downstream vitamin K-dependent genes such as GGCX and coagulation factors.
Why is this activity called warfarin-sensitive?
Because warfarin and other 4-hydroxycoumarin anticoagulants stereoselectively inhibit the enzyme, blocking vitamin K recycling.
What is the role of VKORC1 in this activity?
VKORC1 is the catalytic subunit of the vitamin K epoxide reductase complex and the primary target of warfarin.
How does protein disulfide isomerase affect VKOR activity?
Overexpression of PDI enhances VKOR activity, likely by maintaining the redox state or providing disulfide substrates.
Is vitamin-K-epoxide reductase activity linked to cancer?
Yes, VKORC1L1 regulates p53-mediated tumor suppression through vitamin K metabolism, and VKOR activity modulates androgen receptor signaling.
What diseases are associated with VKORC1 mutations?
VKORC1 mutations can cause warfarin resistance or sensitivity and rare coagulation disorders.
How can I measure vitamin K epoxide reductase activity in the lab?
Enzymatic assays using membrane fractions and HPLC or LC-MS detection of vitamin K epoxide conversion are standard.
What model systems are used to study this activity?
Cell lines with CRISPR knockout, point mutations, knock-in tags, or overexpression of VKORC1 and related genes are commonly used.
Does vitamin K epoxide reductase exist in plants?
Yes, vitamin K epoxide reductase activity has been identified in photosynthetic organisms, indicating evolutionary conservation.
Conclusion
GO:0047057, vitamin-K-epoxide reductase (warfarin-sensitive) activity, is a fundamental molecular function in the vitamin K cycle with critical roles in coagulation, drug response, cancer, and beyond. Its warfarin sensitivity has made it a paradigm for understanding enzyme inhibition and pharmacogenomics. Recent studies linking VKORC1L1 to p53 and androgen receptor signaling highlight its broader biological significance. Continued research using CRISPR models and advanced omics will further illuminate its mechanisms and therapeutic potential.
References
- 1. Yang X et al.. 2023. Regulation of VKORC1L1 is critical for p53-mediated tumor suppression through vitamin K metabolism.. Cell Metab 35(8):1474-1490.e8 PMID: 37467745
- 2. Tew BY et al.. 2017. Vitamin K epoxide reductase regulation of androgen receptor activity.. Oncotarget 8(8):13818-13831 PMID: 28099154
- 3. Chetot T et al.. 2022. Overexpression of protein disulfide isomerase enhances vitamin K epoxide reductase activity.. Biochem Cell Biol 100(2):152-161 PMID: 35007172
- 4. Cain D et al.. 1997. Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane.. J Biol Chem 272(46):29068-75 PMID: 9360981
- 5. Thijssen HH et al.. 1988. Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity.. Br J Pharmacol 95(3):675-82 PMID: 3207986
- 6. Kruk J et al.. 2026. Vitamin K in photosynthetic organisms.. Planta 264(3) PMID: 42570116
- 7. Ledoux J et al.. 2022. Human Vitamin K Epoxide Reductase as a Target of Its Redox Protein.. Int J Mol Sci 23(7) PMID: 35409257
- 8. Stafford DW. 2005. The vitamin K cycle.. J Thromb Haemost 3(8):1873-8 PMID: 16102054
